Scaffolding adapter protein Gab1 impairs bFGF-induced bio-activity via affecting PI3K-AKT pathway.


Journal

Journal of biological regulators and homeostatic agents
ISSN: 0393-974X
Titre abrégé: J Biol Regul Homeost Agents
Pays: Italy
ID NLM: 8809253

Informations de publication

Date de publication:
Historique:
entrez: 31 1 2019
pubmed: 31 1 2019
medline: 18 6 2019
Statut: ppublish

Résumé

The role of Grb2-associated binder 1 (Gab1) in bFGF-activated PI3K-AKT pathway of endothelial cells remains largely unknown. To elucidate this role, a set of studies with siRNA knockdown of Gab1 was performed. Knockdown of Gab1 using siRNA was performed in fused endothelial cell line EA.hy926 and the low level of Gab1 was confirmed with quantitative R-T PCR and Western blotting. Effects of Gab1 down-regulation were examined on several aspects: bFGF-induced AKT phosphorylation, proliferation, migration and vessel tubing formation of EA.hy926 cells. The bFGF-induced AKT phosphorylation of wild-type EA.hy926 cells was both dose-dependent and time dependent with a peak at 10 ng/ml and about 30 min after bFGF treatment. The AKT activation was significantly reduced in Gab1 siRNA-treated EA.hy926 cells. The blocking of Gab1-AKT path resulted in a set of biological alterations of EA.hy926 cells: (i) reduced proliferation; (ii) impaired migration; (iii) decreased vessel tubing formation in both 2D and 3D culture. All data support that Gab1 is associated with angiogenesis function of EA.hy926 endothelium cells via PI3K-Akt signaling pathway.

Identifiants

pubmed: 30697991
pii: 48

Substances chimiques

Adaptor Proteins, Signal Transducing 0
GAB1 protein, human 0
Fibroblast Growth Factor 2 103107-01-3
Phosphatidylinositol 3-Kinases EC 2.7.1.-
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

53-62

Auteurs

J C Zhang (JC)

Department of Vascular Surgery, the First Affiliated Hospital of Fujian Medical University, Abdominal Surgery Institute of Fujian Province, Fuzhou, China.

W X Li (WX)

Department of Vascular Surgery, the First Affiliated Hospital of Fujian Medical University, Abdominal Surgery Institute of Fujian Province, Fuzhou, China.

L Wu (L)

Department of Vascular Surgery, the First Affiliated Hospital of Fujian Medical University, Abdominal Surgery Institute of Fujian Province, Fuzhou, China.

X Liu (X)

Department of Vascular Surgery, the First Affiliated Hospital of Fujian Medical University, Abdominal Surgery Institute of Fujian Province, Fuzhou, China.

L Zhang (L)

Fujian Key Laboratory of Individualized Active Immunotherapy and Key Laboratory of Radiation Biology, Fujian Universities, Fuzhou, China.
Department of Radiation Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China.
Department of Radiation Oncology, University of Florida, Gainesville, Florida, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH